Cerevel Therapeutics (CERE) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Cerevel Therapeutics Revenue Highlights


00

Cerevel Therapeutics Revenue by Period


Cerevel Therapeutics Revenue by Year

DateRevenueChange
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--100.00%
2015-08-31$2.72M13.14%
2014-08-31$2.40M-54.15%
2013-08-31$5.24M-2.38%
2012-08-31$5.37M100.00%
2001-01-01--

Cerevel Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Cerevel Therapeutics Revenue by Quarter

DateRevenueChange
2024-03-31--100.00%
2023-12-31$8.25M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2016-05-31$1.42M303.13%
2016-02-29$351.00K-62.74%
2015-11-30$942.00K10.56%
2015-08-31$852.00K-24.27%
2015-05-31$1.13M227.99%
2015-02-28$343.00K-14.25%
2014-11-30$400.00K17.65%
2014-08-31$340.00K-57.82%
2014-05-31$806.00K62.83%
2014-02-28$495.00K-35.12%
2013-11-30$763.00K-14.94%
2013-08-31$897.00K-33.80%
2013-05-31$1.35M32.20%
2013-02-28$1.02M-47.86%
2012-11-30$1.97M68.90%
2012-08-31$1.16M1.39%
2012-05-31$1.15M-131.10%
2012-02-29$-3.69M-

Cerevel Therapeutics generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Cerevel Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
APLSApellis Pharmaceuticals$366.28M$179.14M
BPMCBlueprint Medicines$249.38M$138.16M
TVTXTravere Therapeutics$145.24M$54.12M
HOWLWerewolf Therapeutics$19.94M$742.00K
RVMDRevolution Medicines, Inc. Warrant$11.58M-
RNAAvidity Biosciences$9.56M$2.04M
IKNAIkena Oncology$9.16M-
STOKStoke Therapeutics$8.78M$4.22M
SWTXSpringWorks Therapeutics$5.45M$21.01M
IGMSIGM Biosciences$2.13M$497.00K
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
GPCRStructure Therapeutics--
NUVLNuvalent--
DAWNDay One Biopharmaceuticals-$8.19M
CERECerevel Therapeutics--
TERNTerns Pharmaceuticals--
VTYXVentyx Biosciences--
MLYSMineralys Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M

CERE Revenue FAQ


Cerevel Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. CERE's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

Cerevel Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $8.25M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). CERE's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).

Cerevel Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.